Pacific Northwest Diabetes Research Institute

Bionano Announces Presentation of OGM Utility Across Key Applications at the American Society of Human Genetics (ASHG) Annual Meeting

Retrieved on: 
Thursday, October 26, 2023

ASHG’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics and genetics research.

Key Points: 
  • ASHG’s annual meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics and genetics research.
  • Dr. Levy will present findings from the largest multisite study to date comparing OGM to classical cytogenetic methods for postnatal constitutional disorder research.
  • Dr. Stevenson will discuss his research using OGM for the analysis of neural tube defects.
  • In addition, 12 posters featuring results from OGM applications in cytogenetic research will be presented at the conference.

Genomic Analysis Reveals Ancient Cancer Lineages in Clams

Retrieved on: 
Monday, October 2, 2023

SEATTLE, Oct. 2, 2023 /PRNewswire-PRWeb/ -- In a new study published in the journal Nature Cancer, Michael Metzger, Ph.D., Assistant Investigator at Pacific Northwest Research Institute (PNRI), and a global team of co-investigators have conducted a comprehensive analysis of the genomic changes associated with a unique cancer in clams. The cancer is "transmissible" in that the cancer cells themselves jump from one clam to another through the environment. The study traced the evolution of the cancer cells over the last 200 years and revealed widespread genomic mutations and instability, which may explain how they have survived for so long. These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.

Key Points: 
  • The cancer is "transmissible" in that the cancer cells themselves jump from one clam to another through the environment.
  • These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.
  • These results highlight the clam's potential as a model for studying both cancer evolution and the development of resilience to cancer.
  • The genomic analysis of cancer in clams advances current knowledge of cancer biology and underscores the importance of studying contagious cancers in their natural settings.

Washington Research Foundation awards $100,000 to Pacific Northwest Research Institute in honor of David J. Galas, Ph.D.

Retrieved on: 
Thursday, August 10, 2023

SEATTLE, Aug. 10, 2023 /PRNewswire-PRWeb/ -- Washington Research Foundation (WRF) has awarded a $100,000 grant to Pacific Northwest Research Institute (PNRI) in honor of David J. Galas, Ph.D., who helped to create the WRF Postdoctoral Fellowship program in 2017 and served on the WRF board of directors from 2010 until his death in May. The grant will support the continuation of work begun by Galas and his colleague Lisa Stubbs, Ph.D., investigating the genetic links between stress and a range of health disorders.

Key Points: 
  • He was a leader in the Human Genome Project and a key contributor to the technology that enabled one of the earliest rapid tests for COVID-19.
  • Galas and his team focused on developing and applying innovative mathematical methods, providing new computational tools to seek out and validate genetic interactions significant to this research.
  • Brooks Simpson, WRF's board chair, said, "David was an incredible board member and mentor to all of us.
  • That will always remain a hallmark of our contributions to the research engines in the region."

Michael Burton, a Veteran Nonprofit Leader, Selected to Lead the Diabetes Research Institute Foundation

Retrieved on: 
Monday, July 17, 2023

MIAMI, July 17, 2023 /PRNewswire/ -- The Diabetes Research Institute Foundation (DRIF), the fundraising arm of the Diabetes Research Institute, a world leader focused on finding a cure for type 1 diabetes, is pleased to announce the appointment of new CEO Michael J. Burton. Burton brings more than three decades of experience to DRIF and will usher in a transformative new era for the Foundation and its affiliated research institute, which are joined in their singular mission to find a cure for diabetes, now.

Key Points: 
  • Prior to joining DRIF, Burton served as a senior-level executive at distinguished institutions including Princeton University, The Pew Charitable Trusts, and the American Association for Cancer Research.
  • "It is a privilege to assume the role of CEO at the Diabetes Research Institute Foundation," said Burton.
  • "I have personally witnessed the unwavering passion, commitment and expertise of the extraordinarily talented scientists at the Diabetes Research Institute.
  • The Foundation provides the DRI with critical funding to pursue promising research and new therapeutic strategies.

Contagious Cancer in Shellfish Sparks Investigation by International Team of Scientists

Retrieved on: 
Thursday, February 9, 2023

SEATTLE, Feb. 9, 2023 /PRNewswire-PRWeb/ -- Michael Metzger, PhD, Assistant Investigator at Pacific Northwest Research Institute, in Seattle, WA, and a team of global co-investigators will study how a virus-like cancer spreads among basket cockles on the Pacific Coast and soft-shell clams on the Atlantic Coast through a $3 million grant from the National Science Foundation's Division of Ocean Sciences.

Key Points: 
  • "We don't normally think of cancer as an infectious disease," said Dr. Metzger.
  • What is unique about this cancer compared to human cancers is that it is transmissible.
  • They found infectious cancer prevalent in local basket cockles, a favorite subsistence species for Tribal members that has become scarce in recent years.
  • Transmissible cancer in soft-shell clams has caused major losses in Massachusetts in the past, severely impacting the commercial fishery.

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Retrieved on: 
Wednesday, February 8, 2023

PHOENIX, Feb. 8, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it has received Institutional Review Board (IRB) approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy. The U.S. Food and Drug Administration (FDA) had previously cleared the Company's Investigational New Drug (IND) application within 30 days from submission.

Key Points: 
  • PHOENIX, Feb. 8, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that it has received Institutional Review Board (IRB) approval to proceed with its Clinical Trial for the treatment of Type 1 Diabetes with its CELZ-201 cell therapy.
  • The U.S. Food and Drug Administration (FDA) had previously cleared the Company's Investigational New Drug (IND) application within 30 days from submission.
  • The primary objective of the study is to evaluate CELZ-201 as a treatment for patients with newly diagnosed Type 1 Diabetes.
  • The company sponsored trial will be conducted at the University of Miami Health System in conjunction with the Diabetes Research Institute.

The Diabetes Research Institute Appoints World-Renowned Diabetes Expert, Matthias von Herrath, M.D., to Scientific Director

Retrieved on: 
Thursday, January 26, 2023

MIAMI, Jan. 26, 2023 /PRNewswire/ -- The Diabetes Research Institute (DRI), a world leader focused on finding a cure for type 1 diabetes, recently announced the appointment of its new scientific director, Matthias von Herrath, M.D. Bringing more than 25 years of experience in diabetes research and innovation, Dr. von Herrath is one of the leading diabetes experts in the world. Dr. von Herrath joins the Miller School after serving as professor at the La Jolla Institute for Immunology in San Diego. He also is Vice President and Senior Medical Officer for Novo Nordisk, Inc., a Danish pharmaceutical company. Dr. von Herrath will leverage his extensive experience opening the door to new frontiers in translational research.  

Key Points: 
  • MIAMI, Jan. 26, 2023 /PRNewswire/ -- The Diabetes Research Institute (DRI) , a world leader focused on finding a cure for type 1 diabetes, recently announced the appointment of its new scientific director, Matthias von Herrath, M.D.
  • Bringing more than 25 years of experience in diabetes research and innovation, Dr. von Herrath is one of the leading diabetes experts in the world.
  • Dr. von Herrath joins the Miller School after serving as professor at the La Jolla Institute for Immunology in San Diego.
  • "We are excited to welcome Dr. von Herrath to the Institute as its new Scientific Director.

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Retrieved on: 
Thursday, November 3, 2022

PHOENIX, Nov. 3, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), an immuno-endocrine company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application, enabling the Company to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem™.

Key Points: 
  • The primary objective of the study (CELZ-201) is to evaluate AlloStemin patients with newly diagnosed Type 1 Diabetes.
  • "This is a milestone event for Creative Medical Technology Holdings as it marks the Company's first IND clearance from the FDA," said Timothy Warbington, CEO.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/creative-medical-technology-hol...
    SOURCE Creative Medical Technology Holdings, Inc.

Alberto Pugliese, M.D., Joins City of Hope as Director of The Wanek Family Project for Type 1 Diabetes and Chair of the Department of Diabetes Immunology

Retrieved on: 
Tuesday, October 18, 2022

LOS ANGELES, Oct. 18, 2022 /PRNewswire/ -- Alberto Pugliese , M.D., has joined City of Hope as the Samuel Rahbar Endowed Chair in Diabetes & Drug Discovery, chair of the Department of Diabetes Immunology, and director of The Wanek Family Project for Type 1 Diabetes within the Arthur Riggs Diabetes & Metabolism Research Institute .

Key Points: 
  • LOS ANGELES, Oct. 18, 2022 /PRNewswire/ -- Alberto Pugliese , M.D., has joined City of Hope as the Samuel Rahbar Endowed Chair in Diabetes & Drug Discovery, chair of the Department of Diabetes Immunology, and director of The Wanek Family Project for Type 1 Diabetes within the Arthur Riggs Diabetes & Metabolism Research Institute .
  • His work has contributed to a greater understanding of genetic and cellular mechanisms that regulate immunological self-tolerance, specifically to molecules targeted in diabetes.
  • Pugliese has provided seminal contributions in the field of type 1 diabetes genetics, immunology, pathology and clinical trials, and his work has been published in major international journals.
  • Pugliese comes to City of Hope by way of the University of Miami, where he served as The J. Enloe and Eugenia J. Dodson Chair in Diabetes Research.

GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 31, 2022

NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financial quarter and full-year ended June 30, 2022 and provided a business update. Management will host a webcast and conference call at 4:30 p.m. ET today.

Key Points: 
  • ET -
    NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time monitoring and diagnostic testing for patients and their primary health practitioners at point of care, today announced its preliminary financial results for the fourth financial quarter and full-year ended June 30, 2022 and provided a business update.
  • We continue our thorough due diligence process and remain on track to update the market in the near term.
  • GBS is now proceeding with the next phase of the glucose biosensor development program, including two key parallel clinical studies.
  • Employee Benefits Expense for the full fiscal year 2022 of $2.3 million compared to the year prior of $1.9 million.